Posted on 3/11/2022
“We applaud CMS for taking action to assist more individuals with diabetes and allowing them to chose the treatments that best fit their diabetes management requirements,” said Jeff Farkas, vice president of Medtronic’s Diabetes unit for health economics, reimbursement, and government relations.
DUBLIN, Ireland, December 22, 2021 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), a worldwide leader in healthcare technology, said today that the Centers for Medicare & Medicaid Services (CMS) in the United States would extend Medicare coverage for all kinds of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs.